• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma.

作者信息

Yu Hui, Sotillo Elena, Harrington Colleen, Wertheim Gerald, Paessler Michele, Maude Shannon L, Rheingold Susan R, Grupp Stephan A, Thomas-Tikhonenko Andrei, Pillai Vinodh

机构信息

Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Pennsylvania.

Division of Cancer Pathobiology, Children's Hospital of Philadelphia, Pennsylvania.

出版信息

Am J Hematol. 2017 Jan;92(1):E11-E13. doi: 10.1002/ajh.24594. Epub 2016 Nov 21.

DOI:10.1002/ajh.24594
PMID:27779774
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8620941/
Abstract
摘要

相似文献

1
Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma.原发性纵隔大B细胞淋巴瘤免疫治疗后靶表面抗原的反复丢失
Am J Hematol. 2017 Jan;92(1):E11-E13. doi: 10.1002/ajh.24594. Epub 2016 Nov 21.
2
CD30 expression is common in mediastinal large B-cell lymphoma.CD30表达在纵隔大B细胞淋巴瘤中很常见。
Am J Clin Pathol. 1999 Aug;112(2):241-7. doi: 10.1093/ajcp/112.2.241.
3
Primary mediastinal large B-cell lymphoma.原发性纵隔大B细胞淋巴瘤
Crit Rev Oncol Hematol. 2017 May;113:318-327. doi: 10.1016/j.critrevonc.2017.01.009. Epub 2017 Jan 21.
4
T-cell leukemia 1 expression in nodal Epstein-Barr virus-negative diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma.T 细胞白血病 1 在结外 EBV 阴性弥漫性大 B 细胞淋巴瘤和原发性纵隔 B 细胞淋巴瘤中的表达。
Hum Pathol. 2010 Sep;41(9):1238-44. doi: 10.1016/j.humpath.2010.01.015. Epub 2010 Apr 10.
5
Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma.弥漫性大B细胞淋巴瘤嵌合抗原受体T细胞治疗后肿瘤表面抗原的序贯性丧失
Haematologica. 2018 May;103(5):e215-e218. doi: 10.3324/haematol.2017.183459. Epub 2018 Feb 1.
6
Discordant expression of immunoglobulin and its associated molecule mb-1/CD79a is frequently found in mediastinal large B cell lymphomas.免疫球蛋白及其相关分子mb-1/CD79a的不一致表达在纵隔大B细胞淋巴瘤中经常被发现。
Am J Pathol. 1995 Mar;146(3):735-41.
7
Relapsed/refractory primary mediastinal large B-cell lymphoma: a structured review of epidemiology, treatment guidelines and real-world treatment practices.复发/难治性原发性纵隔大 B 细胞淋巴瘤：流行病学、治疗指南和真实世界治疗实践的结构化综述。
Expert Rev Hematol. 2020 Mar;13(3):275-287. doi: 10.1080/17474086.2020.1716725. Epub 2020 Jan 28.
8
Prognostic impact of MUM1 expression by immunohistochemistry on primary mediastinal large B-cell lymphoma.免疫组织化学检测 MUM1 表达对原发性纵隔大 B 细胞淋巴瘤的预后影响。
Leuk Lymphoma. 2011 Aug;52(8):1495-503. doi: 10.3109/10428194.2011.573032. Epub 2011 May 31.
9
The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients.原发性纵隔大B细胞淋巴瘤的治疗：98例患者的二十年单中心经验
BMC Cancer. 2017 Apr 17;17(1):276. doi: 10.1186/s12885-017-3269-6.
10
Structural genomic alterations in primary mediastinal large B-cell lymphoma.原发性纵隔大B细胞淋巴瘤中的结构基因组改变。
Leuk Lymphoma. 2015;56(8):2239-50. doi: 10.3109/10428194.2014.985673. Epub 2015 Jan 21.

引用本文的文献

1
Clinical development of immuno-oncology therapeutics.免疫肿瘤治疗药物的临床开发
Cancer Lett. 2025 May 1;617:217616. doi: 10.1016/j.canlet.2025.217616. Epub 2025 Mar 6.
2
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial.嵌合抗原受体巨噬细胞疗法治疗HER2过表达晚期实体瘤：一项1期试验
Nat Med. 2025 Apr;31(4):1171-1182. doi: 10.1038/s41591-025-03495-z. Epub 2025 Feb 7.
3
Revolutionizing cancer treatment: an in-depth exploration of CAR-T cell therapies.颠覆癌症治疗：CAR-T 细胞疗法的深入探索。

本文引用的文献

1
CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity.CD19 CAR 免疫压力诱导 B 前体细胞急性淋巴细胞白血病谱系转换，揭示内在白血病可塑性。
Nat Commun. 2016 Jul 27;7:12320. doi: 10.1038/ncomms12320.
2
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.获得性突变与CD19可变剪接的趋同导致对CART-19免疫疗法产生抗性。
Cancer Discov. 2015 Dec;5(12):1282-95. doi: 10.1158/2159-8290.CD-15-1020. Epub 2015 Oct 29.
3
Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells.
Med Oncol. 2024 Oct 14;41(11):275. doi: 10.1007/s12032-024-02491-6.
4
Current Insights into CAR T-Cell-Based Therapies for Myelodysplastic Syndrome.基于嵌合抗原受体T细胞疗法治疗骨髓增生异常综合征的最新见解
Pharm Res. 2024 Sep;41(9):1757-1773. doi: 10.1007/s11095-024-03761-8. Epub 2024 Aug 26.
5
Complete loss of lineage defining antigens in two cases of B-cell malignancies following CAR-T therapy.两例B细胞恶性肿瘤患者接受嵌合抗原受体T细胞（CAR-T）治疗后谱系定义抗原完全丧失。
J Hematop. 2024 Dec;17(4):259-264. doi: 10.1007/s12308-024-00602-w. Epub 2024 Aug 26.
6
Blockade of the CD47/SIRPα checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamab.阻断CD47/SIRPα检查点轴可增强tafasitamab的巨噬细胞介导的抗肿瘤功效。
Haematologica. 2024 Dec 1;109(12):3928-3940. doi: 10.3324/haematol.2023.284795.
7
Revolutionizing cancer treatment: the power of bi- and tri-specific T-cell engagers in oncolytic virotherapy.革新癌症治疗：双特异性和三特异性T细胞衔接器在溶瘤病毒疗法中的力量
Front Immunol. 2024 Feb 22;15:1343378. doi: 10.3389/fimmu.2024.1343378. eCollection 2024.
8
New immune cell engagers for cancer immunotherapy.用于癌症免疫治疗的新型免疫细胞衔接器。
Nat Rev Immunol. 2024 Jul;24(7):471-486. doi: 10.1038/s41577-023-00982-7. Epub 2024 Jan 25.
9
Standardization of flow cytometric detection of antigen expression.流式细胞术检测抗原表达的标准化。
Cytometry B Clin Cytom. 2024 Jan;106(1):25-34. doi: 10.1002/cyto.b.22155. Epub 2024 Jan 12.
10
Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell-redirecting therapy.淋巴瘤在接受 CD19 和 CD20 靶向 T 细胞重定向治疗后，连续发生抗原丢失和分支进化。
Blood. 2024 Feb 22;143(8):685-696. doi: 10.1182/blood.2023021672.
向浆母细胞淋巴瘤的演变逃避了靶向CD19的嵌合抗原受体T细胞。
Br J Haematol. 2015 Oct;171(2):205-209. doi: 10.1111/bjh.13562. Epub 2015 Jun 18.
4
Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas.单克隆 CD20 抗体治疗在 B 细胞非霍奇金淋巴瘤中的作用和抵抗。
Cancer Treat Rev. 2015 Sep;41(8):680-9. doi: 10.1016/j.ctrv.2015.05.007. Epub 2015 May 19.
5
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.在一项复发/难治性弥漫性大 B 细胞淋巴瘤（DLBCL）的 2 期研究中，贝林妥欧单抗显示出了客观应答，且 CD30 表达存在差异。
Blood. 2015 Feb 26;125(9):1394-402. doi: 10.1182/blood-2014-09-598763. Epub 2015 Jan 8.
6
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.化疗难治性弥漫性大B细胞淋巴瘤和惰性B细胞恶性肿瘤可以用表达抗CD19嵌合抗原受体的自体T细胞进行有效治疗。
J Clin Oncol. 2015 Feb 20;33(6):540-9. doi: 10.1200/JCO.2014.56.2025. Epub 2014 Aug 25.
7
Antibody-modified T cells: CARs take the front seat for hematologic malignancies.抗体修饰的 T 细胞：CARs 在血液恶性肿瘤中占据主导地位。
Blood. 2014 Apr 24;123(17):2625-35. doi: 10.1182/blood-2013-11-492231. Epub 2014 Feb 27.
8
DNA repair genes are selectively mutated in diffuse large B cell lymphomas.DNA 修复基因在弥漫性大 B 细胞淋巴瘤中选择性突变。
J Exp Med. 2013 Aug 26;210(9):1729-42. doi: 10.1084/jem.20122842. Epub 2013 Aug 19.